Background
Phase II prospective trial (Japan). 68 patients with unresectable HCC who were not candidates for surgery, RFA, or liver transplant. Sequential TACE followed by SBRT. TACE performed for all patients, then SBRT given to residual/persistent tumor. SBRT doses: 35–40 Gy in 5 fractions (standard) based on Child-Pugh class and proximity to bowel.
Interventions and follow up
Arm A: Sequential TACE × 1–3 cycles → SBRT 35–40 Gy/5 fractio
Arm B: N/A — single-arm phase II
Primary endpoint: Local control and safety
mFollow up: ~2 year
Arm B: N/A — single-arm phase II
Primary endpoint: Local control and safety
mFollow up: ~2 year
Results
3-year local control: 91%
3-year OS: 70%
Grade 3+ toxicity: 7%
3-year OS: 70%
Grade 3+ toxicity: 7%
Adverse events
Main adverse events: Grade 3+ toxicity 7%; primarily GI (gastric ulcer) and hepatic dysfunction. No grade 5 events. SBRT was generally well tolerated after TACE.
Conclusions
Sequential TACE + SBRT (35–40 Gy/5 fx) achieved 91% 3-year local control and 70% 3-year OS in unresectable HCC, with acceptable toxicity, confirming this combination as a highly effective and well-tolerated treatment strategy for patients not eligible for curative approaches.
Key Limitations
Key Limitations: Single-arm Japanese phase II study — no comparator. Japanese population characteristics (high rate of HBV/HCV-related cirrhosis, specific staging criteria) limit direct generalizability to Western cohorts. Standardized SBRT dose of 35–40 Gy/5 fx may be suboptimal for some tumor sizes vs ablative 3-fraction regimens. TACE protocol not fully standardized across patients.
Clinical Context
This trial adds prospective phase II data to the growing evidence base for TACE+SBRT sequential therapy in unresectable HCC. 91% 3-year LC and 70% 3-year OS are among the best outcomes reported for HCC treated with locoregional therapy. The TACE-first strategy allows targeting of residual viable tumor with SBRT, potentially optimizing dose delivery and minimizing toxicity compared to upfront SBRT for untreated HCC.
References